CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...